← Browse by Condition

Medical Condition

hepatocellular carcinoma

Total Trials

33

Recruiting Now

33

Trial Phases

Phase 1, Phase 3, Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for hepatocellular carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — hepatocellular carcinoma Clinical Trials

How many clinical trials are currently recruiting for hepatocellular carcinoma?

ClinicalMetric currently tracks 33 actively recruiting clinical trials for hepatocellular carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 33. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for hepatocellular carcinoma?

hepatocellular carcinoma research spans Phase 1 (7 trials), Phase 2 (10 trials), Phase 3 (5 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a hepatocellular carcinoma clinical trial?

Eligibility criteria for hepatocellular carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

7

Phase 2

10

Phase 3

5

Top Sponsors

Yonsei University 2 trials

Peking Union Medical College Hospital 1 trial

BeOne Medicines 1 trial

Guangxi Medical University 1 trial

Seoul National University Hospital 1 trial

Recruiting Clinical Trials

NCT06363006 Phase 1

Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer

Peking Union Medical College H...

NCT07836530 Phase 3

Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular Carcinoma

Australia, New Zeala...

BeOne Medicines

NCT05062837 Phase 2, Phase 3

Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC

Guangxi Medical University

Ate-Bev Early Response Prediction Model in Advanced HCC

Seoul National University Hosp...

Early Detection of Liver Cancer by QUS

Centre hospitalier de l'Univer...

InstaSure™ Non-Invasive Finger-Press Test for Hepatocellular Carcinoma

Beijing Municipal Administrati...

NCT02174549 Phase 1, Phase 2

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

NCT04864054 Phase 1, Phase 2

GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC

United States, Taiwa...

Eureka Therapeutics Inc.

Molecular Basis of Pediatric Liver Cancer

University of Pittsburgh

NCT05842174 Phase 1, Phase 2

Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma

VA Office of Research and Deve...

Liver Embolization Approaches for Tumor Management

IRCCS San Raffaele

Impact of Graft Reconditioning With Hypothermic Machine Perfusion on HCC Recurrence After Liver Transplantation

Azienda Ospedaliero-Universita...

Comparison of the Incidence of Delirium Caused by Different Anesthetic Agents in Patients Undergoing Liver Transplantation

Yonsei University

NCT06007846 Phase 2, Phase 3

A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer

Inova Health Care Services

Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma

Assistance Publique - Hôpitaux...

NCT05970666 Phase 2

Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

The First Affiliated Hospital ...

Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment

University of Tennessee

Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing

Tongji Hospital

Improving Hepatocellular Carcinoma Screening

Naik Vietti Violi

NCT06084481 Phase 1

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

United States, Austr...

NCT05516628 Phase 2

Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma

National Cancer Centre, Singap...

NCT07246668 Phase 2

A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma

Yonsei University

Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC

Third Affiliated Hospital, Sun...

68Ga-SorB PET/CT Imaging in Patients With Solid Tumors

Peking University Third Hospit...

An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer

United States, Japan

City of Hope Medical Center

NCT06478693 Phase 1

A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

Australia, South Kor...

Myeloid Therapeutics

NCT06880523 Phase 2

STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

Canadian Cancer Trials Group

Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients

Chinese University of Hong Kon...

NCT06406634 Phase 2

Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma

Hunan Cancer Hospital

NCT05003895 Phase 1

GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies

National Cancer Institute (NCI...

NCT04803994 Phase 3

The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

Austria, France, Ger...

Institut für Klinische Krebsfo...

NCT03895359 Phase 3

Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma

London Health Sciences Centre ...

MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.

Related Conditions

cholangiocarcinoma (4) liver cancer (2) primary liver cancer (2) atezolizumab bevacizumab (1) response evaluation (1) gastrointestinal cancer metastatic (1) neuroendocrine tumors (1) liver cancer adult (1) liver neoplasm (1) metastatic liver cancer (1) childhood liver cancer (1) liver malignant tumors (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology